{"id":"W2338827745","doi":"10.1093/neuonc/nov206.22","title":"ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA","year":2015,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Gliosarcoma; Medicine; Bevacizumab; Glioblastoma; Placebo; Double blinded; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Chemotherapy; Pathology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001933583,0.002377745,0.002841575,0.0005784569,0.0004814767,0.001069089,0.001059745,0.002104623,0.005438308],"category_scores_gemma":[0.001528231,0.000861395,0.001285963,0.0004854324,0.001139761,0.0009382371,0.0003052456,0.00260047,0.0010848],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007091025,"about_ca_system_score_gemma":0.001584054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001036898,"about_ca_topic_score_gemma":0.003000799,"domain_scores_codex":[0.9992977,0.0003687337,0.00004377084,0.0001322242,0.00006568733,0.00009192801],"domain_scores_gemma":[0.9994302,0.0001049566,0.0001343821,0.0000517862,0.00005254125,0.0002260839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9265996,0.02848293,0.000595808,0.0008657142,0.0008009568,0.00006402422,0.00008842154,0.0004676214,0.01508175,0.0001696629,0.001820132,0.02496337],"study_design_scores_gemma":[0.8716013,0.1252584,0.0008903249,0.00001818808,0.0001795507,0.00003313084,0.00001199458,0.0003816534,0.0007284206,0.00008986146,0.0007925475,0.00001465867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804099,0.003351326,0.00117013,0.0006519017,0.0006008453,0.009241165,0.001597855,0.0003624297,0.002614355],"genre_scores_gemma":[0.972883,0.002738124,0.003145767,0.001482187,0.0006685879,0.01207914,0.001680791,0.00006697496,0.005255322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005438308,"threshold_uncertainty_score":0.01819295,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04835993962501408,"score_gpt":0.3525851682394304,"score_spread":0.3042252286144164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}